NTM Infections: Expanding Treatment Access

davidcracc
Email: hmason@delveinsight.com

posted on 2 weeks ago — updated on 1 second ago

6
views

Nontuberculous mycobacterial (NTM) infections are caused by mycobacteria species other than Mycobacterium tuberculosis and commonly lead to chronic pulmonary and extrapulmonary infections. Diagnosing and treating these infections is challenging due to their diverse clinical presentations a

Track the trends in DCM & more—explore the data visually!: <a href="https://www.delveinsight.com/infographics/nontuberculous-mycobacterial-infections-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr">Click Here</a>NTM Infections Epidemiological Segmentation The epidemiological segmentation of NTM infections in the 7MM from 2020 to 2034 covers:<ul><li dir="ltr" aria-level="1">Total prevalent cases </li><li dir="ltr" aria-level="1">Total diagnosed prevalent cases </li><li dir="ltr" aria-level="1">Gender-specific cases </li><li dir="ltr" aria-level="1">Species-specific cases </li><li dir="ltr" aria-level="1">Type-specific cases </li><li dir="ltr" aria-level="1">Severity-specific cases </li></ul>NTM Infections Epidemiology In 2023, the prevalence of NTM infections across the 7MM exhibited distinct trends:<ul><li dir="ltr" aria-level="1">In the US, approximately 108,000 diagnosed prevalent cases were reported. </li><li dir="ltr" aria-level="1">Of these cases, 68% were female, and 32% were male. </li><li dir="ltr" aria-level="1">Among the diagnosed cases, 86,000 were pulmonary NTM infections, while 22,000 were extrapulmonary.</li></ul>Break down the numbers. Understand the strategy. Download the report: <a href="https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr">Click Here</a> NTM Infections Market The US market size for NTM infections was estimated to be around USD 360 million in 2023.NTM Infections Market Drivers The introduction of emerging therapies such as Epetraborole, MNKD-101, and SPR720 is anticipated to significantly enhance the treatment landscape by targeting specific NTM species with improved efficacy and safety.Increased awareness of NTM infections and advances in diagnostic technologies are facilitating earlier diagnosis, improving disease management, and driving market growth.NTM Infections Market Barriers The diversity of NTM species and their variable clinical manifestations complicate treatment approaches and clinical trial designs, making it difficult to predict treatment outcomes.Additionally, high treatment costs and limited access—particularly in underserved areas—remain major challenges to market expansion. NTM Infections Emerging Therapies<ul><li dir="ltr" aria-level="1">Epetraborole </li><li dir="ltr" aria-level="1">MNKD-101 </li><li dir="ltr" aria-level="1">SPR720 </li><li dir="ltr" aria-level="1">And others </li></ul>NTM Infections Key Players<ul><li dir="ltr" aria-level="1">Insmed Incorporated </li><li dir="ltr" aria-level="1">RedHill Biopharma </li><li dir="ltr" aria-level="1">Novoteris </li><li dir="ltr" aria-level="1">Savara Inc. </li><li dir="ltr" aria-level="1">Beyond Air </li><li dir="ltr" aria-level="1">And others </li></ul>Download the full infographic to uncover detailed insights: <a href="https://www.delveinsight.com/infographics/nontuberculous-mycobacterial-infections-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr">Click Here </a>